HIGHLIGHTS

3497 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

3499 Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies
Collin M. Blakely and Caroline E. McCoach
See related article, p. 3525

3501 Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL
Kerry A. Rogers
See related article, p. 3589

3503 Improving AML Classification Using Splicing Signatures
Teresa V. Bowman
See related article, p. 3597

Review

3505 Dissecting the Tumor–Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach
Gregory M. Chen, Andrew Azzam, Yang-Yang Ding, David M. Barrett, Stephan A. Grupp, and Kai Tan

Perspectives

3514 BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)
Elise A. Chong, Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, and Anthony R. Mato

CLINICAL TRIALS: TARGETED THERAPY

3517 Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study
Edwin M. Posadas, Kim N. Chi, Ronald de Wit, Maja J.A. de Jonge, Gerhardt Attard, Terence W. Friedlander, Margaret K. Yu, Peter Helleman, Caly Chien, Charlene Abrams, Juhui J. Jiao, and Fred Saad

3525 A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer
See related commentary, p. 3499

3537 Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors
Florence Atrafi, Ruben A.G. van Eerden, Marte A.M van Hylckama Vlieg, Esther Oomen-de Hoop, Peter de Bruijn, Martijn P. Lolkema, Adriana A. Moolen, Kristianne J. Rijken, Rob Hanssen, Alex Sparreboom, Ferry A.L.M. Esken, Ron H.J. Mathijsen, and Stijn L.W. Koolen

See related article, p. 3507

See related article, p. 3514
3546 Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

3557 Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer
Richard D. Kim, Nilofer S. Azad, Michael A. Morse, Elizabeth Poplin, Amit Mahipal, Benjamin Tan Jr, Sharon A. Mavroukakis, Massimo Fantini, Kwong Y. Tsang, Anjum Zaki, Jose Torrealba, Philip M. Arlen, and Muhammad S. Beg

3565 Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial

3578 Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer

3598 Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

3597 RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia
Gowdhar Anande, Nandan P. Deshpande, Sylvain Mareschal, Aarif M.N. Batcha, Henry R. Hampton, Tobias Herold, Soren Lehmann, Marc R. Wilkins, Jason W.H. Wong, Ashwin Unnikrishnan, and John E. Pimanda

3608 Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer
Anna Moroz, Ying-Hua Wang, Jeremy M. Sharib, Junnian Wei, Ning Zhao, Yangjie Huang, Zhuo Chen, Alexander J. Martinke, Jie Zhuo, Shion A. Lim, Lydia H. Zhang, Youngho Seo, Sean Carlin, Kevin K. Leung, Eric A. Colisson, Kimberly S. Kirkwood, James A. Wells, and Michael J. Evans

3616 Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer
Bohai Feng, Ying Shen, Xavier Pastor Hostench, Matthias Bieg, Michaela Plath, Naveed Ishaque, Roland Els, Kolja Freier, Wilko Weichert, Karim Zaoui, and Jochen Hess
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3629</td>
<td>Comprehensive Genomic Analysis of Translocation in Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression</td>
</tr>
<tr>
<td>3641</td>
<td>A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma</td>
</tr>
<tr>
<td>3649</td>
<td>Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapies in NSCLC</td>
</tr>
<tr>
<td>3662</td>
<td>Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy</td>
</tr>
<tr>
<td>3671</td>
<td>Tumor CD155 Expression Is Associated with Resistance to Anti-CD155 Immunotherapy in Metastatic Melanoma</td>
</tr>
<tr>
<td>3682</td>
<td>Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma</td>
</tr>
<tr>
<td>3694</td>
<td>Predictive Biomarkers to Efficacious Immunotherapy in NSCLC</td>
</tr>
<tr>
<td>3707</td>
<td>AMPK Activation by Metformin Promotes Survival of Dormant ER(^+)/Breast Cancer Cells</td>
</tr>
<tr>
<td>3720</td>
<td>Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts</td>
</tr>
<tr>
<td>3732</td>
<td>TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial</td>
</tr>
<tr>
<td>3740</td>
<td>Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy</td>
</tr>
</tbody>
</table>

# TRANSLATIONAL CANCER MECHANISMS AND THERAPY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3671</td>
<td>Tumor CD155 Expression Is Associated with Resistance to Anti-CD155 Immunotherapy in Metastatic Melanoma</td>
</tr>
</tbody>
</table>

Downloaded from clincancerres.aacrjournals.org on August 6, 2021. © 2020 American Association for Cancer Research.
LETTERS TO THE EDITOR

3889 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Letter
Osamu Maeda, Tomoya Shimokata, and Yuichi Ando

3890 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response
Manish R. Sharma, Smita S. Joshi, and Hedy L. Kindler

3891 Predicted Prognosis of Pancreatic Cancer Patients by Machine Learning—Letter
Julius M. Kernbach and Victor E. Staartjes

3892 Atezolizumab Plus Nab-Paclitaxel in PD-L1–Positive TNBC—Letter
Sara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, Andrea Rocca, Michela Palleschi, Maurizio Puccetti, Paola Parrella, Mattia Altini, and Roberta Maltoni

ABOUT THE COVER

The cover shows a high magnification microscopic image of the tumor bed from a patient with resected non-small cell lung cancer treated with neoadjuvant nintedanib plus chemotherapy. The image demonstrates approximately 40% residual viable tumor with a mixed inflammatory infiltrate and marked fibroelastotic changes following treatment. For details, see the article by Cascone and colleagues on page 3525 of this issue.